Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA

BACKGROUND: Radium‐223 prolongs overall survival in patients with castration‐resistant prostate cancer (CRPC) and symptomatic bone metastases, regardless of prior docetaxel. Whether or not chemotherapy can be safely administered following radium‐223 treatment is of clinical importance. An explorator...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartor, Oliver, Hoskin, Peter, Coleman, Robert E., Nilsson, Sten, Vogelzang, Nicholas J., Petrenciuc, Oana, Staudacher, Karin, Thuresson, Marcus, Parker, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071661/
https://www.ncbi.nlm.nih.gov/pubmed/27004570
http://dx.doi.org/10.1002/pros.23180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071661/
https://www.ncbi.nlm.nih.gov/pubmed/27004570
http://dx.doi.org/10.1002/pros.23180

Ejemplares similares